#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	4144	16S	1529	1529	99.87	16S.l6.c4.ctg.1	2461	491.7	0	.	n	.	0	A69G	SNP	69	69	A	471	471	G	586	G,A	538,2	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	4144	16S	1529	1529	99.87	16S.l6.c4.ctg.1	2461	491.7	0	.	n	.	0	C1450T	SNP	1450	1450	C	1852	1852	T	585	T,C,G	536,1,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	4144	16S	1529	1529	99.87	16S.l6.c4.ctg.1	2461	491.7	1	SNP	n	C1184T	0	.	.	1184	1184	C	1586	1586	C	617	C,A	556,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6550	23S	2890	2890	99.93	23S.l6.c4.ctg.1	4231	464.2	0	.	n	.	0	T695C	SNP	695	695	T	1279	1279	C	510	C,A	444,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6550	23S	2890	2890	99.93	23S.l6.c4.ctg.1	4231	464.2	0	.	n	.	0	T1971C	SNP	1971	1971	T	2555	2555	C	601	C,A	538,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6550	23S	2890	2890	99.93	23S.l6.c4.ctg.1	4231	464.2	1	SNP	n	A2045G	0	.	.	2045	2045	A	2629	2629	A	614	A	561	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6550	23S	2890	2890	99.93	23S.l6.c4.ctg.1	4231	464.2	1	SNP	n	C2597T	0	.	.	2597	2597	C	3181	3181	C	557	C,G	496,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_O_01412c	folP.WHO_O_01412c	1	1	27	718	folP	855	855	100.0	folP.l6.c4.ctg.1	2057	104.6	1	SNP	p	R229S	1	.	.	685	687	AGC	1337	1339	AGC	165;166;166	A;G;C	139;150;148	folP.WHO_O_01412c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	1466	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3967	110.8	1	SNP	p	S91F	1	.	.	271	273	TTC	883	885	TTC	140;140;141	T;T;C	128;127;129	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	1466	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3967	110.8	1	SNP	p	G95N	0	.	.	283	285	GGC	895	897	GGC	138;139;139	G;G;C	127;126;124	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	1466	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3967	110.8	1	SNP	p	D95G	1	.	.	283	285	GGC	895	897	GGC	138;139;139	G;G;C	127;126;124	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	539	650	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1824	107.0	0	.	p	.	0	D79N	NONSYN	235	237	GAT	794	796	AAT	178;178;178	A,G;A;T	162,1;162;156	.	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	539	650	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1824	107.0	1	SNP	p	G45D	0	.	.	133	135	GGC	692	694	GGC	164;164;163	G,T;G;C,T	148,1;147;147,1	mtrR.WHO_U_01459:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	434	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1640	79.5	0	.	n	.	0	A197.	DEL	197	197	A	988	988	A	153	A	141	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1388	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3385	122.2	0	.	p	.	0	E91G	NONSYN	271	273	GAG	802	804	GGG	140;141;141	G,T;G,A;G	131,1;130,1;131	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1388	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3385	122.2	1	SNP	p	D86N	0	.	.	256	258	GAC	787	789	GAC	147;147;147	G;A;C	131;131;130	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1388	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3385	122.2	1	SNP	p	S87W	0	.	.	259	261	AGT	790	792	AGT	147;148;148	A;G;T	130;134;135	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1388	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3385	122.2	1	SNP	p	S87R	0	.	.	259	261	AGT	790	792	AGT	147;148;148	A;G;T	130;134;135	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1388	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3385	122.2	1	SNP	p	S87I	0	.	.	259	261	AGT	790	792	AGT	147;148;148	A;G;T	130;134;135	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1388	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3385	122.2	1	SNP	p	S88P	0	.	.	262	264	TCC	793	795	TCC	148;148;148	T;C;C	133;131;131	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	1334	parE	1986	1986	99.9	parE.l15.c4.ctg.1	3132	127.6	0	.	p	.	0	R427H	NONSYN	1279	1281	CGC	1836	1838	CAC	167;168;169	C;A;C	146;150;151	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	1334	parE	1986	1986	99.9	parE.l15.c4.ctg.1	3132	127.6	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1785	1787	GGC	157;158;156	G;G;C	139;146;142	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.49.001	penA.49.001	1	1	27	1170	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2882	121.6	1	SNP	p	A311V	0	.	.	931	933	GCA	1555	1557	GCA	180;179;178	G;C;A	165;164;166	penA.49.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.49.001	penA.49.001	1	1	27	1170	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2882	121.6	1	SNP	p	I312M	0	.	.	934	936	ATC	1558	1560	ATC	178;178;178	A;T;C	163;160;166	penA.49.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.49.001	penA.49.001	1	1	27	1170	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2882	121.6	1	SNP	p	V316T	0	.	.	946	948	GTG	1570	1572	GTG	179;179;180	G;T;G	167;165;165	penA.49.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.49.001	penA.49.001	1	1	27	1170	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2882	121.6	1	SNP	p	V316P	0	.	.	946	948	GTG	1570	1572	GTG	179;179;180	G;T;G	167;165;165	penA.49.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.49.001	penA.49.001	1	1	27	1170	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2882	121.6	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2074	2076	ACC	155;154;154	A,C;C;C	134,1;126;136	penA.49.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.49.001	penA.49.001	1	1	27	1170	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2882	121.6	1	SNP	p	T502V	0	.	.	1504	1506	ACG	2128	2130	ACG	147;147;147	A,G;C,A;G,T,C	119,1;111,1;117,2,1	penA.49.001:1:1:T502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.49.001	penA.49.001	1	1	27	1170	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2882	121.6	1	SNP	p	T502P	0	.	.	1504	1506	ACG	2128	2130	ACG	147;147;147	A,G;C,A;G,T,C	119,1;111,1;117,2,1	penA.49.001:1:1:T502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.49.001	penA.49.001	1	1	27	1170	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2882	121.6	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2251	2253	GGC	148;148;149	G,C;G;C,A	130,1;135;138,1	penA.49.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.49.001	penA.49.001	1	1	27	1170	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2882	121.6	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2260	2262	GGC	148;149;149	G;G;C	129;133;135	penA.49.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.49.001	penA.49.001	1	1	27	1170	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2882	121.6	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2278	2280	CCG	145;146;146	C;C;G,C	117;130;120,1	penA.49.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	1586	ponA	2397	2397	100.0	ponA.l6.c4.ctg.1	3814	124.7	1	SNP	p	L421P	1	.	.	1261	1263	CCG	2127	2129	CCG	149;149;149	C,T;C;G	126,1;135;130	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	748	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2237	99.9	0	.	p	.	0	M83fs	FSHIFT	247	247	A	713	713	C	116	C	101	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	118	porB1a	984	292	90.2	porB1a.l15.c4.ctg.1	1519	22.9	0	.	p	.	0	H217N	NONSYN	649	651	CAT	1252	1254	AAT	4;4;4	A;A;T	4;4;4	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	118	porB1a	984	292	90.2	porB1a.l15.c4.ctg.1	1519	22.9	0	.	p	.	0	D218N	NONSYN	652	654	GAT	1255	1257	AAT	4;4;4	A;A;T	4;4;4	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	118	porB1a	984	292	90.2	porB1a.l15.c4.ctg.1	1519	22.9	0	.	p	.	0	V226A	NONSYN	676	678	GTA	1279	1281	GCA	4;4;4	G;C;A	4;4;4	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	118	porB1a	984	292	90.2	porB1a.l15.c4.ctg.1	1519	22.9	0	.	p	.	0	.	MULTIPLE	700	702	ACT	1302	1304	GTA	2;2;2	G;T;A	2;2;2	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	118	porB1a	984	292	90.2	porB1a.l15.c4.ctg.1	1519	22.9	0	.	p	.	0	S236N	NONSYN	706	708	AGC	1308	1310	AAC	2;2;2	A;A;C	2;2;2	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	118	porB1a	984	292	90.2	porB1a.l15.c4.ctg.1	1519	22.9	0	.	p	.	0	.	MULTIPLE	709	711	AAC	1312	1316	TGGCG	2;2;2;2;2	T;G;G;C;G	1;2;2;2;2	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	118	porB1a	984	292	90.2	porB1a.l15.c4.ctg.1	1519	22.9	0	.	p	.	0	D238A	NONSYN	712	714	GAT	1318	1320	GCT	2;2;2	G;C;T	2;2;2	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	118	porB1a	984	292	90.2	porB1a.l15.c4.ctg.1	1519	22.9	0	.	p	.	0	V258L	NONSYN	772	774	GTA	1378	1380	TTA	2;2;2	T;T;A	2;2;2	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	118	porB1a	984	292	90.2	porB1a.l15.c4.ctg.1	1519	22.9	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	1423	1425	CAT	2;2;2	C;A;T	2;2;2	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	118	porB1a	984	292	90.2	porB1a.l15.c4.ctg.1	1519	22.9	0	.	p	.	0	D274S	NONSYN	820	822	GAT	1426	1428	AGT	2;2;2	A;G;T	2;2;2	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	118	porB1a	984	292	90.2	porB1a.l15.c4.ctg.1	1519	22.9	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	1435	1437	TAC	2;2;2	T;A;C	2;2;2	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	902	porB1b	1047	1047	99.04	porB1b.l15.c4.ctg.1	2178	123.2	0	.	p	.	0	T26A	NONSYN	76	78	ACC	782	784	GCC	226;226;229	G;C;C	193;199;195	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	902	porB1b	1047	1047	99.04	porB1b.l15.c4.ctg.1	2178	123.2	0	.	p	.	0	N38E	NONSYN	112	114	AAT	818	820	GAA	225;226;226	G;A;A	192;194;197	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	902	porB1b	1047	1047	99.04	porB1b.l15.c4.ctg.1	2178	123.2	0	.	p	.	0	N124S	NONSYN	370	372	AAT	1076	1078	AGT	206;206;206	A;G;T,G	181;181;178,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	902	porB1b	1047	1047	99.04	porB1b.l15.c4.ctg.1	2178	123.2	0	.	p	.	0	N134D	NONSYN	400	402	AAT	1106	1108	GAT	197;198;196	G;A;T	174;170;171	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	902	porB1b	1047	1047	99.04	porB1b.l15.c4.ctg.1	2178	123.2	0	.	p	.	0	P175S	NONSYN	523	525	CCA	1229	1231	TCA	172;170;170	T,C;C;A	157,1;158;154	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	902	porB1b	1047	1047	99.04	porB1b.l15.c4.ctg.1	2178	123.2	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1358	1360	GTC	156;155;154	G;T,G;C	142;141,1;140	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	902	porB1b	1047	1047	99.04	porB1b.l15.c4.ctg.1	2178	123.2	0	.	p	.	0	F222S	NONSYN	664	666	TTT	1370	1372	TCT	154;153;152	T;C;T	137;138;138	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	902	porB1b	1047	1047	99.04	porB1b.l15.c4.ctg.1	2178	123.2	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1688	1690	GCA	134;134;134	G;C;A	123;122;120	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	902	porB1b	1047	1047	99.04	porB1b.l15.c4.ctg.1	2178	123.2	1	SNP	p	G120K	1	.	.	358	360	AAG	1064	1066	AAG	205;204;205	A;A,C;G,T	179;177,1;184,1	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	902	porB1b	1047	1047	99.04	porB1b.l15.c4.ctg.1	2178	123.2	1	SNP	p	A121D	1	.	.	361	363	GAC	1067	1069	GAC	206;205;205	G;A;C	174;178;178	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	902	porB1b	1047	1047	99.04	porB1b.l15.c4.ctg.1	2178	123.2	1	SNP	p	D121N	0	.	.	361	363	GAC	1067	1069	GAC	206;205;205	G;A;C	174;178;178	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	2922	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5410	161.9	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2232	2234	CAT	182;182;181	C;A,C;T	167;165,1;167	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	404	rpsJ	312	312	100.0	rpsJ.l6.c4.ctg.1	1510	80.3	1	SNP	p	V57M	1	.	.	169	171	ATG	813	815	ATG	149;149;149	A;T;G	136;137;133	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
